Cramer Rosenthal Mcglynn LLC Grows Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Cramer Rosenthal Mcglynn LLC lifted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 3.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,706,225 shares of the company's stock after buying an additional 89,031 shares during the quarter. Elanco Animal Health makes up 1.9% of Cramer Rosenthal Mcglynn LLC's investment portfolio, making the stock its 15th largest position. Cramer Rosenthal Mcglynn LLC owned about 0.55% of Elanco Animal Health worth $32,772,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new position in shares of Elanco Animal Health during the 3rd quarter valued at about $35,000. Jones Financial Companies Lllp boosted its holdings in shares of Elanco Animal Health by 95.6% in the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after purchasing an additional 2,059 shares during the last quarter. SRS Capital Advisors Inc. grew its stake in shares of Elanco Animal Health by 221.2% during the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock valued at $60,000 after buying an additional 3,411 shares during the period. MRP Capital Investments LLC acquired a new stake in shares of Elanco Animal Health during the 4th quarter worth $61,000. Finally, Blue Trust Inc. raised its position in shares of Elanco Animal Health by 47.7% in the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after buying an additional 1,894 shares during the period. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Price Performance

ELAN opened at $8.44 on Friday. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $18.80. The firm has a market cap of $4.19 billion, a price-to-earnings ratio of 21.11, a PEG ratio of 2.50 and a beta of 1.44. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The company has a fifty day simple moving average of $10.32 and a 200 day simple moving average of $11.89.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the prior year, the business earned $0.08 earnings per share. The firm's revenue was down 1.4% on a year-over-year basis. Equities research analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ELAN shares. Barclays cut their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Morgan Stanley reduced their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 26th. Piper Sandler dropped their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, March 6th. Stifel Nicolaus reduced their target price on shares of Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating on the stock in a report on Monday. Finally, UBS Group lowered their price target on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $14.67.

Insider Buying and Selling at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius bought 10,000 shares of the company's stock in a transaction dated Tuesday, March 11th. The stock was bought at an average price of $10.20 per share, with a total value of $102,000.00. Following the transaction, the director now owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 0.57% of the stock is currently owned by corporate insiders.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.